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Abstract 1 
We investigated whether a rejection episode in one graft was associated with rejection 2 
in the other graft, in recipients with bilateral corneal transplants. In a prospectively-3 
maintained, national register of 14,865 followed corneal grafts, 1,476 patients with 4 
bilateral penetrating corneal grafts were identified. Occurrence of rejection was a risk 5 
factor for graft failure (p<0.0001). Logistic regression was used to calculate the adjusted 6 
odds ratio for rejection in one eye following rejection in the other eye. In the subset of 7 
1,118 patients with bilateral grafts but no history of previous grafts or rejections in either 8 
eye, the adjusted odds ratio for a rejection episode in the first eye following rejection in 9 
the second was 3.27 (95% CI 1.85, 5.79; p<0.001). The adjusted odds ratio was 2.04 10 
(95% CI 1.07, 3.91; p=0.03) for rejection in the second eye following rejection in the 11 
first. The median time between the first rejection episode in one eye and the first 12 
rejection episode in the other eye was 15 months. Patients with bilateral corneal grafts 13 
who suffer a graft rejection episode in one eye are at significantly greater odds of 14 
suffering a rejection episode in the other corneal transplant. 15 
16 
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Introduction 1 
Irreversible corneal graft rejection is a common cause of human corneal transplant 2 
failure (1, 2). In any cohort of patients with penetrating corneal grafts, a proportion may 3 
have bilateral grafts. Over twenty years ago, Meyer reviewed the literature on the likely 4 
influence of a second corneal graft on the risk of rejection in either eye in patients with 5 
bilateral grafts, and was unable to draw firm conclusions from the available data (3). In 6 
a more recent study, Musch and Meyer studied 90 patients with bilateral grafts, with 7 
follow-up ranging from 4-108 months for both eyes considered together, and concluded 8 
that there was no increased risk of rejection in the first eye after penetrating 9 
keratoplasty in the second eye (4). 10 
 11 
We were interested in a rather different question: specifically, whether the occurrence of 12 
a rejection episode in either grafted eye would affect the risk of rejection in the graft in 13 
the other eye. This issue has some implications for clinical management, and is also of 14 
interest to investigators exploring the mechanisms involved in corneal graft rejection. 15 
Accordingly, we identified 1,476 patients with bilateral corneal grafts in a prospectively-16 
collected clinical database containing records of 14,865 penetrating corneal grafts 17 
followed for 1 to 24 years, and investigated the influence of bilateral transplantation on 18 
the risk of rejection in either eye.  19 
 20 
Subjects and Methods 21 
Australian Corneal Graft Register 22 
The Australian Corneal Graft Register was established in May 1985 to follow the 23 
outcomes associated with corneal transplants performed nationally. Records of corneal 24 
transplantation and subsequent follow-up have been submitted by 634 ophthalmic 25 
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surgeons and other practitioners. Individual surgeons handle the consent process for 1 
each patient according to local legislative requirements, to permit information to be 2 
lodged with the register. The institutional Clinical Ethics Committee of Flinders 3 
University oversees the operations of the register, which are carried out in accordance 4 
with the Declaration of Helsinki. 5 
 6 
Data collection and verification 7 
Using well-validated proformas, data were collected on the recipient, donor, eye bank, 8 
operative procedure, post-operative management and post-operative course, as 9 
previously described (5). Each corneal graft was followed at yearly intervals until graft 10 
failure or until the death or loss to follow-up of the patient. Missing data were routinely 11 
sought by follow-up letter to the contributing ophthalmologist or Eye Bank, as 12 
appropriate. Data verification is inherent in the database structure, which contains 13 
internal logic checks, but all records were independently verified by a second individual 14 
against the record provided by the contributor.  15 
 16 
Donor corneas 17 
All donor corneas were assessed within a licensed Eye Bank on the basis of the history, 18 
slit-lamp analysis of the enucleated globes, and specular microscopy to confirm a 19 
normal corneal endothelium. Serological testing to exclude some communicable 20 
diseases was also performed. Advanced donor age was no specific barrier to donation, 21 
and tissue matching of donor and recipient was not performed. 22 
 23 
Definition of specified events before and after corneal transplantation 24 
Information was collected on specific risk factors for corneal graft failure (5). A history of 25 
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past inflammation was recorded if the individual was reported to have had such an 1 
episode, if the patient had had one or more previous grafts or any previous intraocular 2 
surgery in the same eye, or if there was a history of topical glucocorticosteroids use in 3 
the two weeks immediately preceding the graft. Vessel ingrowth into the cornea at the 4 
time of graft was scored on a scale of 0-4 (5). No distinction was made between 5 
superficial or deep vessels, patent or ghost vessels, or single or multiple vessel 6 
leashes. Intraocular pressure (IOP) was considered to be raised if a reading of ≥25 mm 7 
mercury was made by applanation tonometry, but the final decision was at the 8 
discretion of the ophthalmologist. Indications for transplantation, post-operative 9 
complications and reasons for graft failure were coded using the International 10 
Classification of Diseases system (ICD.9.CM, US Department of Health and Human 11 
Services). To examine the influence of graft diameter, recipient bed size rather than 12 
donor button size was used. 13 
 14 
Primary non-functions were defined as grafts that never thinned and cleared in the 15 
immediate post-operative period. The trial time in survival analysis for such grafts was 16 
arbitrarily adjusted to one day. Any existing graft that was replaced by another in the 17 
same eye, irrespective of graft clarity and for whatever reason, was classified as a failed 18 
graft. In all other cases, graft failure was defined as oedema and irremediable loss of 19 
clarity in a previously thin, transparent graft. The day of failure was the first day the 20 
patient was seen with an oedematous, opaque graft that subsequently failed to thin and 21 
clear. Rejection was defined as the development of inflammation and an epithelial or 22 
endothelial rejection line and/or a unilateral anterior chamber reaction with corneal 23 
infiltrates and spreading corneal oedema in a previously thin, transparent graft. Graft 24 
failure can occur from causes other than rejection, and a rejection episode may be 25 
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reversible or irreversible. 1 
 2 
Recipients with bilateral grafts 3 
At the census date of October 2009, the Registry held records of 19,387 penetrating 4 
corneal grafts in 21,279 patients. Of the 19,387 grafts, 14,865 (77%) had been followed 5 
on at least one annual occasion. Records with archival follow-up were available for 6 
2,952 grafts in 1,476 individuals with bilateral corneal grafts. No recipient of bilateral 7 
grafts had received two corneas from the same donor. For inclusion in this study, we 8 
considered only recipients in whom a graft was performed in the second eye, in the 9 
presence of a functioning graft in the other eye (the first eye). Thus, both grafts in both 10 
eyes were concurrently transparent immediately after the surgery in the second eye. 11 
Follow-up after surgery in the second eye extended for a median of 31 months (range 12 
1-249 months, with short times reflecting graft failure). 13 
 14 
Statistical analyses 15 
Data were amalgamated and de-identified prior to analysis using the software packages 16 
SPSS v15 (SPSS Inc, Chicago, IL) and Stata v9 (StataCorp, College Station, TX). The 17 
Pearson chi-square test was used to compare demographics and indications for corneal 18 
transplantation in patients with bilateral grafts compared with all penetrating grafts, with 19 
the significance level set at 0.05. Column percentages for each relevant category in the 20 
cohort of all grafts were used to generate expected frequencies in the cohort with 21 
bilateral grafts. The chi-square test was also used to test for associations between 22 
rejection episodes in first and second eyes of patients with bilateral grafts, and to test 23 
any association of recipient sex with rejection episodes. Kaplan-Meier survival functions 24 
(6-8) were constructed to provide a graphical record of graft survival. For surviving 25 
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grafts, trial time was calculated as the time between the date of graft and the date on 1 
which the patient was last seen. For failed grafts, trial time was calculated as the time 2 
between the date of graft and the date of failure. Kaplan-Meier plots were also used to 3 
determine rejection-free survival times. The log-rank statistic was used to examine 4 
differences amongst plots. A Cox proportional hazards model was used for multivariate 5 
survival analysis to determine risk factors for graft survival in the bilateral cohort. 6 
Clustering by patient accounted for the correlation between eyes (9). A backwards 7 
selection process was used to find statistically significant covariates (p≤0.05). 8 
 9 
Matched logistic regression was used to determine whether the first or second grafted 10 
eye was more at risk for rejection (10). Subsequently, subset analysis was performed 11 
using each patient as the unit of analysis, to calculate the adjusted odds ratio for a 12 
rejection episode in one grafted eye following a rejection episode in the other grafted 13 
eye. Potential confounders considered in multivariate analyses are shown in Table 1; 14 
graft size was square root-transformed to ensure linearity. Variables were checked for 15 
confounding status using Pearson’s  test for association with rejection episodes in first 16 
and second eyes, and univariate logistic regression. Multivariate analysis included all 17 
variables with associations at p≤0.1, in a forward selection process. Variables that were 18 
not significant (p≤0.05) in the multivariate logistic regression were excluded from the 19 
final model. A non-parametric K-sample test was used to test the equality of median 20 
times to rejection in each eye of patients with bilateral grafts. Further survival analysis 21 
was performed with time to rejection (after the second eye was grafted) as the trial time. 22 
For patients with one or more rejections in the same eye, time after rejection was 23 
analysed separately (10). 24 
 25 
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 1 
Results 2 
Demographics of patients with bilateral grafts 3 
The demographics of recipients of bilateral grafts compared with the cohort of all 4 
penetrating grafts are shown in Table 2. The cohorts were comparable, except that 5 
patients with bilateral corneal grafts were significantly younger at transplantation 6 
(p<0.001). The indications for transplantation (Table 3) in patients with bilateral grafts 7 
differed significantly from those of the total cohort (p<0.001), in that more patients 8 
required transplantation for keratoconus or a corneal dystrophy (conditions which are 9 
frequently bilateral) in the former. The relative excess of patients with bilateral 10 
transplants who were grafted for keratoconus explains the younger age distribution in 11 
this cohort, as keratoconus typically manifests itself during adolescence. 12 
 13 
Influence of rejection on corneal graft survival in the total cohort of penetrating 14 
grafts 15 
We first examined the influence of rejection episodes (whether reversible or irreversible) 16 
on graft survival in the cohort of all penetrating grafts (Figure 1). The occurrence of one 17 
or more rejection episodes was a significant risk factor for corneal graft failure (log-rank 18 
statistic p<0.0001). Of the 14,865 penetrating corneal grafts followed, 3,442 had failed 19 
and 1,126 (33%) of these had failed from irreversible graft rejection.  20 
 21 
Influence of rejection episodes in patients with bilateral grafts 22 
We next examined the cohort of patients with bilateral corneal grafts. Of the 2,952 grafts 23 
in 1,476 patients, 376 grafts had failed and of these, 110 (29%) had failed from 24 
irreversible rejection. The occurrence of one or more rejection episodes was a 25 
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significant risk factor (p<0.0001) for graft failure in univariate analysis (Figure 2) and a 1 
significant independent risk factor for graft failure in Cox proportional hazards 2 
regression (Table 4). Overall, risk factors for graft failure in the cohort with bilateral 3 
corneal grafts were similar to those previously reported for the total cohort of 4 
penetrating grafts (1, 11). 5 
 6 
The occurrence of at least one rejection episode (after the second eye was grafted) in 7 
neither, either or both eyes of 1,476 patients with bilateral grafts was then investigated. 8 
Irreversible plus reversible rejection episodes, irreversible rejection episodes only, and 9 
reversible rejection episodes only, were examined separately (Table 5). Irrespective of 10 
whether rejection episodes were reversible or irreversible, the Pearson 2 test indicated 11 
a significantly different number of rejection episodes between the two eyes. Further 12 
one-sided Fisher’s exact testing showed that second eyes had a significantly higher 13 
number of rejection episodes than first eyes (p<0.001). In subsequent analyses, all 14 
rejection episodes (irreversible plus reversible) were considered together. 15 
 16 
In some instances, a recipient with bilateral grafts had had a history of rejection 17 
episodes in a graft in one or both eyes, prior to the index graft in the second eye (Table 18 
6). Using the subset of 1,316 patients who had not previously suffered a rejection 19 
episode in any graft in either eye, prior to the index graft in the second eye, matched 20 
logistic regression was performed to analyse which eye was more likely to undergo graft 21 
rejection (Table 7). The adjusted odds ratio for a rejection episode in the second of the 22 
two bilateral grafts compared with the first was 2.21 (95% confidence interval (CI) 1.62, 23 
3.02; p<0.001). Corneal neovascularization in the graft was a significant covariate in this 24 
analysis. Further matched logistic regression was performed to analyse whether the 25 
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order of bilateral rejection episodes was significant: it was not, with an odds ratio of 1.21 1 
(95% CI 0.66, 2.22; p=0.54) for second eyes rejecting before first eyes.  2 
 3 
Next, logistic regression analysis using the patient (rather than the eye) as the unit of 4 
analysis was performed, to examine the influence of a rejection episode in either graft 5 
on the likelihood of a subsequent rejection episode in the graft in the other eye. 6 
Rejections in the first and second grafted eyes of 1,316 bilateral graft recipients who 7 
had no previous history of graft rejection in either eye were analysed (Table 8). With 8 
rejection in eye one as the outcome, the adjusted odds ratio was 2.99 (95% CI 1.79, 9 
5.02; p<0.001) for rejection in eye two, compared with no rejection in eye two. Similarly, 10 
the adjusted odds ratio was 2.15 (95% CI 1.22, 3.78; p=0.008) for rejection in eye two 11 
following rejection in eye one, compared with no rejection in eye one. 12 
 13 
The analysis was then repeated in the subset of 1,118 patients with bilateral grafts, but 14 
with no history of previous grafts or rejections in either eye (Table 9). For a rejection 15 
episode in the first eye following rejection in the second, the adjusted odds ratio was 16 
3.27 (95% CI 1.85, 5.79; p<0.001). For a rejection episode in the second eye following 17 
rejection in the first, the adjusted odds ratio was 2.04 (95% CI 1.07, 3.91; p=0.03). 18 
Significant covariates were corneal neovascularization and keratoconus. Thus, after an 19 
episode of rejection in one graft, the odds of a rejection episode in the other graft were 20 
significantly increased, irrespective of whether the episode was reversible or led to graft 21 
failure, and irrespective of past history of corneal transplantation or occurrence of 22 
rejection episodes. 23 
 24 
Time to rejection in patients with bilateral corneal grafts 25 
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The median times at which rejection occurred in the 1,476 patients with bilateral grafts 1 
were examined (Table 10). Although in some instances an episode of corneal graft 2 
rejection in the first eye was followed swiftly by an episode in the other eye, the median 3 
time between rejection episodes in bilateral grafts was approximately 15 months. In 21 4 
first-grafted eyes with a previous rejection in the same graft, a further rejection occurred 5 
after the second eye was grafted. For the total bilateral cohort and in eyes with no 6 
previous rejection, median times from transplantation to the first rejection episode after 7 
the second eye was grafted were similar; a test for equality of medians showed no 8 
difference for eyes with and without previous rejections (continuity corrected Pearson 9 
χ2(1)=0.19, p=0.66 for eye one; χ2(1)=1.54, p=0.21 for eye two). Thus, a history of 10 
previous rejection did not influence the median time to rejection in the same eye. 11 
 12 
Since each bilateral graft may have suffered multiple rejection episodes, the effect of a 13 
rejection episode at any time after graft on subsequent rejection episodes was 14 
examined. Time after each rejection episode was analysed separately. There were 15 
2,601 grafts with no rejection episodes, 289 with one, 44 with two, 18 with three, plus 16 
258 rejection-free periods following a rejection episode. Patients with previous 17 
rejections in both eyes were excluded, leaving 1,501 at risk for the first eye and 1,659 18 
for the second eye. Kaplan-Meier plots were generated to examine the effect of 19 
rejection episodes in either the same or opposite eye on subsequent rejection (Figure 20 
3). Grafts with a history of one or more rejections in either eye had significantly worse 21 
(p<0.001) rejection-free survival compared with grafts with no such history. Grafts with 22 
previous rejections in the opposite eye had significantly worse rejection-free survival 23 
than grafts with no previous rejections, but better rejection-free survival than grafts with 24 
previous rejections in the same eye (p<0.0001).  25 
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 1 
History of systemic sensitization in patients with bilateral corneal grafts 2 
The data were consistent with the possibility that the occurrence of a rejection episode 3 
in the contralateral eye was associated with a history of systemic sensitization of the 4 
recipient. A potential confounding factor might thus be recipient systemic sensitization 5 
to foreign histocompatibility antigens present on a fetus, resulting from a past 6 
pregnancy. Gender was not associated with rejection in the first grafted eye (Pearson’s 7 
2(1)=1.01, p=0.31), therefore gender was not a risk factor in the analysis. A history of 8 
pregnancy was thus unlikely to have accounted for the finding that a rejection episode 9 
in the graft in one eye predisposes the recipient to rejection in a graft in the other eye. 10 
 11 
12 
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Discussion 1 
Using Registry data, we report that in a cohort of patients with bilateral corneal grafts, 2 
the occurrence of a rejection episode was a significant risk factor for graft failure. 3 
Second eyes to be grafted suffered significantly more rejection episodes than first eyes 4 
to be grafted. In recipients of bilateral grafts who had no previous history of rejection in 5 
either eye, those who suffered a graft rejection episode in one eye were then at a 6 
significantly greater risk of suffering a rejection episode in the graft in the other eye. A 7 
similar finding was observed when the subset of patients who had never had a previous 8 
graft nor a rejection episode in either eye was examined. The median time between 9 
rejection episodes in bilateral grafts was 15 months.  10 
 11 
Registries, increasingly being used to fill evidence-gaps that may not be amenable to 12 
randomised controlled clinical trials (12), have inherent strengths and weaknesses. 13 
Strengths include the long-term follow-up of patients who have undergone a surgical 14 
intervention “in the real world”. In the context of this study, the approach is accepting of 15 
individual surgeon variations in case selection, surgical technique and post-operative 16 
management, important because corneal transplantation is performed in a mixture of 17 
practice settings. In Australia, all donor corneas must be provided by a licensed Eye 18 
Bank and corneal grafts reported to the Registry, so that case ascertainment is high. 19 
The major weakness is loss to follow-up, which can occur either because the death of a 20 
recipient has not been notified to the contributing ophthalmologist, or because the 21 
recipient has chosen not to attend a scheduled appointment. However, all patients with 22 
corneal grafts are counselled to seek medical attention, should they notice symptoms of 23 
corneal graft rejection such as pain, reddening of the eye, or decreased visual acuity. 24 
The non-random selection of cases with rejection episodes is unlikely to have been an 25 
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issue, and patients with bilateral grafts were followed for a median of 31 months after 1 
corneal transplantation in the second eye. However, a potential source of uncontrolled 2 
variation relates to the immunosuppressive regimen provided to corneal graft recipients. 3 
There is no gold standard for the prophylaxis or treatment of corneal graft rejection (2). 4 
Systemic immunosuppression is seldom used, and although all grafts are treated with 5 
topical glucocorticosteroids, the type of steroid, concentration, and regimen of 6 
administration vary considerably (13). 7 
 8 
All our analyses support the contention that an episode of rejection in one corneal graft 9 
significantly increases the odds of rejection of a graft in the other eye. There are at least 10 
two possible explanations for our findings, which have not to our knowledge been 11 
reported previously in humans. The individual patient who suffers rejection episodes in 12 
both grafts may conceivably be immunologically hyper-reactive and therefore prone to 13 
rejection. An alternative scenario, which we favour, is that the patient has become 14 
systemically sensitized to mismatched histocompatibility antigens present on the graft in 15 
one eye, some of which are also present on the graft in the contralateral eye. 16 
 17 
Despite being considered as an immune-privileged site, the eye is not sequestered from 18 
the immune system (14). It has been known for over 35 years that the combination of 19 
corneal graft neovascularization, inflammation, and deliberate systemic sensitization to 20 
donor antigens will together ensure penetrating corneal graft rejection in outbred 21 
experimental models (15). In a model of orthotopic corneal transplantation in the inbred 22 
rat, a second orthotopic corneal graft in either a previously grafted ipsilateral eye or into 23 
the normal contralateral eye was rejected at an accelerated tempo compared with the 24 
first ipsilateral graft, but the second graft was rejected at the same tempo irrespective of 25 
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the eye into which it was placed, suggesting that systemic sensitization had occurred as 1 
a result of the first graft (16). The phenomenon of anterior chamber-associated immune 2 
deviation, in which introduction of foreign antigen into the anterior chamber of 3 
experimental animals results in a systemic depression of the delayed type 4 
hypersensitivity response to that antigen (17), is further evidence of an interaction (albeit 5 
immunomodulatory) between the eye and the systemic immune response. The relative 6 
immune privilege enjoyed by the normal cornea and anterior segment is, however, 7 
readily broken by the sequelae of neovascularization and inflammation (2, 18), and 8 
human corneal recipients with long-surviving grafts are probably not truly tolerant, in 9 
that rejection generally occurs once immune privilege has been perturbed. 10 
 11 
The relatively long lag time that we observed between rejection episodes in bilateral 12 
corneal grafts in some of our patients might argue against the likelihood that systemic 13 
sensitization to histoincompatible antigens present on one graft had generated effector 14 
cells that were poised to react to the other graft, that by chance carried some of the 15 
same incompatible antigens. Should such effector cells have been generated by direct 16 
antigen presentation (19) for example, then a more immediate rejection response might 17 
have been expected. However, although the median time between rejection episodes in 18 
the ipsilateral and contralateral grafts was 15 months, the range was very wide. 19 
Furthermore, immune responsiveness was very probably modulated by the 20 
administration of topical glucocorticosteroid prophylaxis in all patients. Our data are 21 
consistent with the operation of either direct or indirect antigen presentation, or both, 22 
occurring to induce systemic sensitization in the individual patient. 23 
 24 
Irrespective of the mechanisms involved, our findings have clinical ramifications. 25 
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Corneal endothelial cell loss is a major risk factor for late penetrating corneal graft 1 
failure (20-22), and thus even reversible rejection episodes may compromise corneal 2 
graft survival and function. Patients with bilateral corneal grafts who have suffered a 3 
rejection episode in one grafted eye should be counselled to seek prompt ophthalmic 4 
care in the event that they notice any untoward symptoms in either eye, and 5 
ophthalmologists may need to consider carefully, the timeframe over which topical 6 
steroids are prescribed. In instances where a graft failure has occurred and a repeat 7 
keratoplasty is being contemplated, then consideration might be given to maintenance 8 
of topical immunosuppression in the longer term. It is of some concern in this context 9 
that although topical glucocorticoid treatment is widely considered to be the gold 10 
standard for the prevention and treatment of corneal graft rejection, there is little good 11 
evidence to guide selection of the corticosteroid or indeed, any other 12 
immunosuppressive drug (23), or the regimen of administration (24) in the post-13 
operative period. Tissue matching, found to be useful in some but not all studies (25, 14 
26) may be another option when contemplating bilateral corneal transplantation in 15 
patients with high-risk indications for graft. Further, careful consideration should be 16 
given to the need for a corneal graft in the second eye of a patient at high-risk for 17 
rejection, who has achieved good vision in a graft in the first eye. Irreversible rejection 18 
remains a major cause of corneal graft loss (1, 11, 23, 27, 28), and there is a clear need 19 
for an improved evidence-base for the prevention and treatment of rejection, to support 20 
clinical practice. 21 
 22 
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Table 1: Risks factors examined as potential confounders in multivariate logistic 1 
regression analysis of 1,476 recipients with bilateral corneal grafts 2 
______________________________________________________________________ 3 
Risk factor     Category   Number recipients 4 
          (percent) 5 
______________________________________________________________________ 6 
Sex of recipient    Female    756  (51%) 7 
      Male     720  (49%) 8 
Recipient age at first graft   <60 years     995  (67%) 9 
      60 years     481  (33%) 10 
Graft era (for first eye grafted)  1985-1996 inclusive    968  (65%) 11 
      1997-2009 inclusive    508 (34%) 12 
Corneal vascularization at graft,  0 quadrants   1,235  (84%) 13 
 first eye    1-4 quadrants    241  (16%) 14 
Corneal vascularization at graft,  0 quadrants   1,259  (85%) 15 
 second eye    1-4 quadrants    217  (15%) 16 
Inflammation in first eye,   No      999  (67%) 17 
 in past and/or at graft  Yes      477 (32%) 18 
Inflammation in second eye,  No    1,042  (71%) 19 
 in past and/or at graft  Yes      434  (29%) 20 
Keratoconus as bilateral indication No      705  (48%) 21 
 for graft    Yes      771  (52%) 22 
History of previous graft in first eye No    1,300  (88%) 23 
      Yes      176  (12%) 24 
History of previous graft in second eye No    1,302  (88%) 25 
      Yes      174  (12%) 26 
Graft size      distance from 8 mm diameter 1,476 (100%) 27 
Neovascularization of first graft  No    1,409  (95%) 28 
      Yes        67   (5%) 29 
Neovascularization of second graft No    1,427  (97%) 30 
      Yes        49   (3%) 31 
______________________________________________________________________ 32 
33 
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Table 2. Demographics of 2,952 bilateral corneal grafts in 1,476 recipients of bilateral 1 
grafts, compared with the total cohort of 14,865 penetrating corneal grafts 2 
___________________________________________________________ 3 
Demographic    Bilateral grafts Total cohort 4 
___________________________________________________________ 5 
Female     1,510 (51%)  7,337 (49%) 6 
Male      1,442 (49%)  7,528 (51%) 7 
Age*  <30 years at graft     849 (29%)  2,809 (19%) 8 
  30-59 years at graft  1,068 (36%)  4,700 (32%) 9 
  >=60 years at graft  1,035 (35%)  7,349 (49%) 10 
Corneal neovascularisation     116 ( 4%)     964 ( 6%) 11 
Graft size <7 mm diameter      31 ( 1%)     207 ( 1%) 12 
  7.0 – 7.4 mm      296 (10%)  1,639 (12%) 13 
  7.5 – 7.9 mm   1,194 (42%)  6,092 (43%) 14 
  8.0 – 8.4 mm   1,152 (41%)  5,265 (37%) 15 
  8.5 – 8.9 mm      123 ( 4%)     610 ( 4%) 16 
  9.0 – 9.9 mm       33 ( 1%)     213 ( 2%) 17 
  =>10 mm       6 ( <1%)     110 ( 1%) 18 
Era  1985-1988      301 (10%)  1,689 (11%) 19 
  1989-1992      681 (23%)   3,553 (24%) 20 
  1993-1996      621 (21%)  2,894 (20%) 21 
  1997-2000      609 (21%)  2,747 (18%) 22 
  2001-2004      573 (19%)   2,826 (19%) 23 
  2005-2009      167 ( 6%)  1,156 ( 8%) 24 
____________________________________________________________ 25 
2 (2)=141.5; p<0.001 for difference between cohort with bilateral grafts and total 26 
cohort, in respect (only) of recipient age at graft. 27 
28 
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Table 3: Indications for transplantation in 2,952 eyes of 1,476 patients with bilateral 2 
corneal grafts, compared with indications in the total cohort of 14, 865 penetrating 3 
corneal grafts 4 
________________________________________________________________ 5 
Indication    Bilateral grafts  Total cohort 6 
________________________________________________________________ 7 
Keratoconus     1,532 (52%)     5,249 (35%) 8 
Bullous keratopathy     429 (15%)     3,908 (26%) 9 
Failed previous graft    335 (11%)     1,817 (12%) 10 
Corneal dystrophy     439 (15%)     1,336 ( 9%) 11 
Other       217 ( 7%)     2,555 (17%) 12 
Total     2,952 (100%)   14,865 (100%) 13 
________________________________________________________________ 14 
2 (4)=353.3; p<0.001 for difference between cohort with bilateral grafts and total 15 
cohort. 16 
 17 
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Table 4: Significant risk factors for graft failure in 1476 patients with bilateral corneal grafts: Cox proportional hazards regression 1 
____________________________________________________________________________________________ 2 
Variable          Hazard ratio (95% CI)      p 3 
____________________________________________________________________________________________ 4 
Rejection episode/s     No    1.0 5 
       Yes    3.01 (2.13, 4.26)  p<0.001 6 
Keratoconus      No    1.0 7 
       Yes    0.26 (0.17, 0.40)  p<0.001 8 
Corneal vascularization at graft   0 quadrants   1.0 9 
       1 or more quadrants 1.56 (1.01, 2.42)  p=0.045 10 
Vascularization post graft    No    1.0 11 
       Yes    2.04 (1.05, 3.96)  p=0.04 12 
Aphakia      No    1.0 13 
       Yes    2.16 (1.24, 3.78)  p=0.007 14 
Postoperative microbial keratitis   No    1.0 15 
       Yes    3.16 (1.70, 5.84)  p<0.001 16 
Raised intraocular pressure at graft  No    1.0 17 
       Yes    9.45 (2.30, 38.8)  p=0.002 18 
Arrangements for follow-up   By surgeon   1.0 19 
       Elsewhere   0.52 (0.32, 0.85)  p=0.008 20 
Removal of graft sutures  Every unit increase in ln (year)  0.76 (0.60, 0.95)  p=0.02 21 
Graft size    √ distance from 8 mm diameter  1.85 (1.13, 3.00)  p=0.01 22 
23 
Rejection in bilateral corneal grafts 25 
Table 5: Occurrence of rejection episode/s in neither, either or both eyes of 1,476 patients with bilateral penetrating corneal grafts 1 
___________________________________________________________________________________________________ 2 
Type of rejection episode     Rejection episode     2 (1)  p 3 
             in eye two 4 
        No  Yes  Total 5 
___________________________________________________________________________________________________ 6 
All episodes,  Rejection episode No  1,176 (80%) 167 (11%) 1,343 (91%)  64.5  p<0.001 7 
  (irreversible+   in eye one  Yes     82 ( 5%)   51 (4%)   133 ( 9%) 8 
reversible)     Total  1,258 (85%) 218 (15%) 1,476 (100%) 9 
 10 
Irreversible  Rejection episode No  1,374 (93%)  43 (3%) 1,417 (96%)  18.8  p<0.001 11 
  episodes only   in eye one  Yes     51 (4%)   8 (<1%)   59 (4%) 12 
      Total  1,425 (97%)  51 (3%) 1,476 (100%) 13 
 14 
Reversible  Rejection episode No  1,264 (86%) 138 (9%) 1,402 (95%)  60.3  p<0.001 15 
  episodes only   in eye one   Yes      45 (3%)  29 (2%)   74 (5%) 16 
      Total  1,309 (89%) 167 (11%) 1,476 (100%) 17 
___________________________________________________________________________________________________ 18 
19 
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Table 6: History of previous rejection episodes (reversible or irreversible) in 1,476 recipients with bilateral corneal grafts 2 
_______________________________________________________________________________________________ 3 
Risk factor            Number recipients (percent) 4 
_______________________________________________________________________________________________ 5 
Rejection episode in previous graft in first grafted eye         32* (2%) 6 
Rejection episode in first grafted eye, prior to graft in second eye      121* (8%) 7 
Rejection episode in previous graft in second grafted eye        18* (1%) 8 
No prior rejection episode in any graft in either eye at time of graft in second eye  1316 (89%) 9 
______________________________________________________________________________________________ 10 
* Note categories are not mutually exclusive. 11 
 12 
13 
Rejection in bilateral corneal grafts 27 
 1 
Table 7: Subset analysis: unadjusted and adjusted odds ratios for rejection in the second eye compared with the first eye in 1,316 2 
recipients* of bilateral grafts who had not previously suffered a rejection episode in any graft in either eye 3 
________________________________________________________________________________________________________ 4 
Covariate     Unadjusted odds ratio for rejection p Adjusted odds ratio for rejection  p 5 
           (95% CI)         (95% CI) 6 
________________________________________________________________________________________________________ 7 
Eye number    One  1.0       1.0 8 
     Two  2.11 (1.56, 2.86)  p<0.001  2.21 (1.62, 3.02)  p<0.001 9 
Vascularization in grafted eye No  1.0       1.0 10 
     Yes  3.60 (1.34, 9.70)  p=0.01  4.45 (1.56, 12.70)  p=0.005 11 
________________________________________________________________________________________________________ 12 
*1,081 patients (82%) had no rejections in either eye, 62 (5%) had rejections in eye one only, 131 (10%) had rejections in eye two 13 
only and 42 (3%) had rejections in both eyes. 14 
 15 
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Table 8: Unadjusted and adjusted odds ratios for rejection, for each eye treated separately, in 1,316 recipients of bilateral corneal 2 
grafts* who had not previously suffered a rejection episode in any graft in either eye 3 
________________________________________________________________________________________________________ 4 
Outcome  Significant   Unadjusted odds ratio for rejection p Adjusted odds ratio for rejection p 5 
   covariate     (95% CI)     (95% CI) 6 
________________________________________________________________________________________________________  7 
Rejection episode Rejection episode,  No 1.0       1.0 8 
in eye one  eye two   Yes 3.06 (1.84, 5.11)  p<0.001  2.99 (1.79, 5.02) p<0.001 9 
   Vascularization of  No 1.0       1.0 10 
   graft in eye one  Yes 3.62 (1.75, 7.50)  p=0.001  3.46 (1.65, 7.26) p=0.001 11 
Rejection episode Rejection episode,  No 1.0       1.0 12 
in eye two  eye one   Yes 2.53 (1.47, 4.36)   p=0.001  2.15 (1.22, 3.78) p=0.008 13 
   Keratoconus   No 1.0       1.0 14 
       Yes 0.59 (0.42, 0.81)  p=0.001  0.54 (0.38, 0.77 p=0.001 15 
   Vascularization of  No 1.0       1.0 16 
   graft in eye two  Yes 5.19 (2.77, 9.74)  p<0.001  4.94 (2.54, 9.62) p<0.001 17 
________________________________________________________________________________________________________ 18 
*1,081 patients (82%) had no rejections in either eye, 62 (5%) had rejections in eye one only, 131 (10%) had rejections in eye two 19 
only, 19 (1%) had a rejection in eye one followed by a rejection in eye two, and 23 (2%) had a rejection in eye two followed by a 20 
rejection in eye one. 21 
22 
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Table 9: Unadjusted and adjusted odds ratios for rejection, for each eye considered separately, in 1,118 patients* with bilateral 1 
grafts but no history of previous grafts or rejections in either eye 2 
________________________________________________________________________________________________________ 3 
Outcome  Covariate  Unadjusted odds ratio for rejection p Adjusted odds ratio for rejection  p 4 
        (95% CI)     (95% CI) 5 
________________________________________________________________________________________________________ 6 
Rejection episode Rejection episode,  No 1.0      1.0 7 
in eye one  eye two   Yes 3.37 (1.92, 5.93)  p<0.001 3.27 (1.85, 5.79)  p<0.001 8 
    Vascularization of  No 1.0      1.0 9 
   graft in eye one  Yes 3.84 (1.71, 8.68)  p=0.001 3.61 (1.57, 8.29)  p=0.002 10 
Rejection episode Rejection episode,  No 1.0      1.0 11 
in eye two  eye one   Yes 2.48 (1.33, 4.64)   p=0.004 2.04 (1.07, 3.91)  p=0.03 12 
   Keratoconus   No 1.0      1.0 13 
       Yes 0.58 (0.40, 0.83)  p=0.003  0.50 (0.34, 0.75)  p=0.001 14 
   Vascularization of  No 1.0      1.0 15 
   graft in eye two  Yes 5.77 (2.76, 12.1)  p<0.001 5.32 (2.40, 11.8)  p<0.001 16 
________________________________________________________________________________________________________ 17 
*932 patients (83%) had no rejections in either eye, 52 (5%) had rejections in eye one only, 101 (9%) had rejections in eye two only, 18 
14 (1%) had a rejection in eye one followed by a rejection in eye two, 19 (2%) had a rejection in eye two followed by a rejection in 19 
eye one. 20 
21 
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Table 10: Time between transplantation and rejection episodes in 1,476 patients with bilateral corneal grafts 2 
__________________________________________________________________________________________ 3 
Time (months) between:        Median Range 4 
__________________________________________________________________________________________ 5 
Transplant (date of graft, eye one) and first rejection episode in eye one   54   5-258 6 
Transplant (date of graft, eye two) and first rejection episode in eye two   12  <1-190 7 
First rejection in either eye and first rejection in other eye     15  <1-197 8 
First rejection in eye one and second rejection in eye one      3    1-35 9 
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Figure Legends 1 
 2 
Figure 1. Kaplan-Meier survival plot of all penetrating corneal grafts with follow-up, 3 
stratified according to the occurrence or otherwise of episodes of corneal graft rejection. 4 
This univariate analysis was performed on the complete dataset (n=14,865) without 5 
patient clustering. The numbers at risk at intervals of 3 years are shown below the plot. 6 
The difference between the curves is significant at p<0.0001 (log-rank statistic). 7 
 8 
Figure 2. Kaplan-Meier survival plot of penetrating corneal grafts in recipients of 9 
followed bilateral grafts, stratified according to the occurrence or otherwise of episodes 10 
of corneal graft rejection. This univariate analysis was performed on the complete data 11 
set (n=2,952) without patient clustering. The numbers at risk at intervals of 3 years are 12 
shown below the plot. The difference between the curves is significant at p<0.0001 (log-13 
rank statistic). 14 
 15 
Figure 3. Kaplan-Meier plot of rejection-free survival stratified by first and second eyes 16 
separately, with and without previous rejection episodes in the same eye or the 17 
opposite eye, for the cohort of recipients with bilateral grafts. After a rejection episode, 18 
time to a subsequent rejection in the same eye was analysed as separate event, giving 19 
1,501 at risk for the first eye (Eye 1) and 1,659 for the second eye (Eye 2) to be grafted. 20 
The numbers at risk at intervals of three years are shown below the plot (n/a = not 21 
applicable). The differences between the curves in each set of plots (Eye 1, Eye 2) are 22 
significant at p< 0.0001 (log-rank statistic).  23 
Figure 1 
Identity 
Number at risk, years post graft 
Initially 3 6 9 12 15 18 21 
No rejection 
episodes 12,086 4,534 2,292 1,169 629 296 95 21 
≥1 rejection 
episodes 2,279 1,232 657 329 161 66 19 7 
Figure 2 
Identity 
Number at risk, years post graft 
Initially 3 6 9 12 15 18 21 
No rejection 
episodes 2,504 1,368 793 442 265 135 53 12 
≥1 rejection 
episodes 448 304 198 109 53 24 12 6 
Figure 3 













No history of 
previous rejection 1192 560 290 154 90 38 9 0 
History of previous 
rejection in eye one 146 48 18 7 6 2 1 n/a 
History of previous 
rejection in eye two 163 90 56 31 16 8 2 n/a 













No history of 
previous rejection 1372 572 300 163 90 36 8 1 
History of previous 
rejection in eye two 183 55 29 15 4 2 1 n/a 
History of previous 
rejection in eye one 104 61 38 21 8 4 2 n/a 
Eye 1 
Eye 2 
